Post-HCT NGS-MRD correlations
| . | . | . | Relapse . | |
|---|---|---|---|---|
| Number of post-HCT NGS-MRD . | Positive, n . | Patients, n . | N . | % . |
| No. of tests | ||||
| None | — | 3 | 0 | 0 |
| 1 | 0 | 6 | 1 | 17 |
| 1 | 1 | 2 | 1 | 50 |
| 2 | 0 | 15 | 4 | 27 |
| 2 | 1 | 4 | 2 | 50 |
| 2 | 2 | 1 | 1 | 100 |
| 3-4 | 0 | 17 | 0 | 0 |
| 3-4 | 1 | 5 | 4 | 80 |
| 3-4 | 2+ | 3 | 3 | 100 |
| . | . | . | Relapse . | |
|---|---|---|---|---|
| Number of post-HCT NGS-MRD . | Positive, n . | Patients, n . | N . | % . |
| No. of tests | ||||
| None | — | 3 | 0 | 0 |
| 1 | 0 | 6 | 1 | 17 |
| 1 | 1 | 2 | 1 | 50 |
| 2 | 0 | 15 | 4 | 27 |
| 2 | 1 | 4 | 2 | 50 |
| 2 | 2 | 1 | 1 | 100 |
| 3-4 | 0 | 17 | 0 | 0 |
| 3-4 | 1 | 5 | 4 | 80 |
| 3-4 | 2+ | 3 | 3 | 100 |
| NGS-MRD status pre- and post-HCT* . | . | . | . | |
|---|---|---|---|---|
| Pre-HCT . | Positive post-HCT . | . | . | . |
| Negative | 0 | 19 | 0 | 0 |
| Negative | 1+ | 2 | 0 | 0 |
| Positive | 0 | 7 | 1 | 14 |
| Positive | 1+ | 10 | 8 | 80 |
| NGS-MRD status pre- and post-HCT* . | . | . | . | |
|---|---|---|---|---|
| Pre-HCT . | Positive post-HCT . | . | . | . |
| Negative | 0 | 19 | 0 | 0 |
| Negative | 1+ | 2 | 0 | 0 |
| Positive | 0 | 7 | 1 | 14 |
| Positive | 1+ | 10 | 8 | 80 |
| Post-HCT deep-sequence and flow MRD . | . | . | . | |
|---|---|---|---|---|
| Positive NGS-MRD . | Positive MFC-MRD* . | . | . | . |
| 0 | 0 | 35 | 5 | 14 |
| 0 | 1+ | 3 | 0 | 0 |
| 1+ | 0 | 11 | 7 | 64 |
| 1+ | 1+ | 3 | 3 | 100 |
| Post-HCT deep-sequence and flow MRD . | . | . | . | |
|---|---|---|---|---|
| Positive NGS-MRD . | Positive MFC-MRD* . | . | . | . |
| 0 | 0 | 35 | 5 | 14 |
| 0 | 1+ | 3 | 0 | 0 |
| 1+ | 0 | 11 | 7 | 64 |
| 1+ | 1+ | 3 | 3 | 100 |
Among patients with at least 1 post-HCT assessment (3 patients had a pre- but no post-HCT NGS-MRD performed, and 1 patient had post-HCT NGS-MRD but no post-HCT MFC-MRD).